January 13, 2022
Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
Media
January 12, 2022
Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway
January 11, 2022
Fusion Pharmaceuticals Announces Research Collaboration With 48Hour Discovery To Develop Peptide-Based Radiopharmaceuticals
January 11, 2022
Fusion Pharmaceuticals Announces Research Collaboration With Pepscan To Develop Peptide-Based Radiopharmaceuticals
January 10, 2022
Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development
January 10, 2022
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
January 07, 2022
Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma
January 05, 2022
Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team
January 05, 2022
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
January 05, 2022
Oncopeptides announces year-end cash 2021
